DOCSLIB.ORG

Syntheses and Analytical Characterizations of N-Alkyl-Arylcyclohexylamines

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Syntheses and Analytical Characterizations of N-Alkyl-Arylcyclohexylamines LJMU Research Online Wallach, J, Colestock, T, Cicali, B, Elliott, SP, Kavanagh, PV, Adejare, A, Dempster, NM and Brandt, SD Syntheses and analytical characterizations of N-alkyl-arylcyclohexylamines. http://researchonline.ljmu.ac.uk/id/eprint/3240/ Article Citation (please note it is advisable to refer to the publisher’s version if you intend to cite from this work) Wallach, J, Colestock, T, Cicali, B, Elliott, SP, Kavanagh, PV, Adejare, A, Dempster, NM and Brandt, SD (2015) Syntheses and analytical characterizations of N-alkyl-arylcyclohexylamines. Drug Testing and Analysis. ISSN 1942-7611 LJMU has developed LJMU Research Online for users to access the research output of the University more effectively. Copyright © and Moral Rights for the papers on this site are retained by the individual authors and/or other copyright owners. Users may download and/or print one copy of any article(s) in LJMU Research Online to facilitate their private study or for non-commercial research. You may not engage in further distribution of the material or use it for any profit-making activities or any commercial gain. The version presented here may differ from the published version or from the version of the record. Please see the repository URL above for details on accessing the published version and note that access may require a subscription. For more information please contact [email protected] http://researchonline.ljmu.ac.uk/ Drug Testing and Analysis Syntheses and analyti cal characterizations of N -alkyl - arylcyclohexylamines Journal:For Drug Peer Testing and Analysis Review Manuscript ID: DTA-15-0185.R1 Wiley - Manuscript type: Research Article Date Submitted by the Author: n/a Complete List of Authors: Wallach, Jason; University of the Sciences, Department of Pharmaceutical Sciences Colestock, Tristan; University of the Sciences, Department of Pharmaceutical Sciences Cicali, Brian; University of the Sciences, Department of Pharmaceutical Sciences Elliott, Simon; ROAR Rorensics, Kavanagh, Pierce; School of Medicine, Trinity Centre for Health Sciences, St. James Hospital, Department of Pharmacology and Therapeutics Adejare, Adeboye; University of the Sciences, Department of Pharmaceutical Sciences Dempster, Nicola; Liverpool John Moores University, School of Pharmacy and Biomolecular Sciences Brandt, Simon; School of Pharmacy & Biomolecular Sciences , Liverpool John Moores University New psychoactive substances, Research chemicals, Phencyclidine, NMDA Keywords: receptors, Arylcyclohexylamines The rise in new psychoactive substances that are available as ‘research chemicals’ (RCs) remains a significant forensic and legislative challenge. A number of arylcyclohexylamines have attracted attention as RCs and continued to be encountered, including 3-MeO-PCP, 3-MeO-PCE and 3- MeO-PCPr. These compounds are commonly perceived as ketamine-like dissociative substances and are believed to act predominantly via antagonism of the N-methyl-D-aspartate (NMDA) receptor. To aid in the identification of newly emerging substances the syntheses of fifteen N- alkyl-arylcyclohexylamines are described. Analytical characterizations were Abstract: performed via gas chromatography and high performance liquid chromatography coupled to multiple forms of mass spectrometry as well as nuclear magnetic resonance spectroscopy, ultraviolet diode array detection and infrared spectroscopy. The series consisted of the N-alkyl derivatives (N-methyl, N-ethyl, N-propyl) of phenyl-substituted and isomeric 2-, 3- and 4-methoxy phenylcyclohexylamines, as well as the N-alkyl derivatives obtained from a 3-methylphenyl and 2-thienyl moiety. In addition to the presentation of a range of previously unreported data, it was also found that positional isomers of aryl methoxyl-substituted arylcyclohexylamines were readily distinguishable under a variety of analytical conditions. http://mc.manuscriptcentral.com/dta Page 1 of 34 Drug Testing and Analysis 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 For Peer Review 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 http://mc.manuscriptcentral.com/dta Drug Testing and Analysis Page 2 of 34 1 2 3 Syntheses and analytical characterizations of N-alkyl- 4 5 arylcyclohexylamines 6 7 Jason Wallach a, Tristan Colestock a, Brian Cicali a, Simon P. Elliott b, Pierce 8 V. Kavanagh c, Adeboye Adejare a, Nicola M. Dempster d, Simon D. Brandt d,* 9 10 11 a 12 Department of Pharmaceutical Sciences, Philadelphia College of Pharmacy, University of 13 the Sciences, Philadelphia, PA 19104, USA 14 15 b ROAR Forensics, Malvern Hills Science Park, Geraldine Road, WR14 3SZ, UK 16 17 c Department of Pharmacology and Therapeutics, School of Medicine, Trinity Centre for 18 Health Sciences,For St. James Hospital,Peer Dublin 8, IrelanReviewd 19 20 d School of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, Byrom 21 22 Street, Liverpool L3 3AF, UK 23 24 25 *Correspondence to: Simon D. Brandt, School of Pharmacy and Biomolecular Sciences, 26 Liverpool John Moores University, Byrom Street, Liverpool, L3 3AF, UK. E-Mail: 27 [email protected] 28 29 Running title: Characterization of N-alkyl-arylcyclohexylamines 30 31 32 33 Abstract 34 35 The rise in new psychoactive substances that are available as ‘research chemicals’ 36 37 (RCs) remains a significant forensic and legislative challenge. A number of 38 arylcyclohexylamines have attracted attention as RCs and continued to be 39 encountered, including 3-MeO-PCP, 3-MeO-PCE and 3-MeO-PCPr. These 40 compounds are commonly perceived as ketamine-like dissociative substances and 41 are believed to act predominantly via antagonism of the N-methyl-D-aspartate 42 43 (NMDA) receptor. To aid in the identification of newly emerging substances the 44 syntheses of fifteen N-alkyl-arylcyclohexylamines are described. Analytical 45 characterizations were performed via gas chromatography and high performance 46 liquid chromatography coupled to multiple forms of mass spectrometry as well as 47 nuclear magnetic resonance spectroscopy, ultraviolet diode array detection and 48 infrared spectroscopy. The series consisted of the N-alkyl derivatives ( N-methyl, N- 49 50 ethyl, N-propyl) of phenyl-substituted and isomeric 2-, 3- and 4-methoxy 51 phenylcyclohexylamines, as well as the N-alkyl derivatives obtained from a 3- 52 methylphenyl and 2-thienyl moiety. In addition to the presentation of a range of 53 previously unreported data, it was also found that positional isomers of aryl methoxyl- 54 substituted arylcyclohexylamines were readily distinguishable under a variety of 55 analytical conditions. 56 57 58 59 60 http://mc.manuscriptcentral.com/dta 1 Page 3 of 34 Drug Testing and Analysis 1 2 3 Keywords: New psychoactive substances; ‘research chemicals’; phencyclidine; 4 NMDA receptors; arylcyclohexylamines 5 6 7 Introduction 8 9 The non-medical use of dissociative drugs including 1-(1-phenylcyclohexyl)piperidine 10 (PCP), ketamine and their derivatives is a challenge to policy makers, clinicians and 11 forensic investigators charged with their identification. More recent examples of 12 13 dissociative drugs include ‘research chemicals’ (RCs) such as 3-MeO-PCP, [1-4] 14 methoxetamine (MXE), diphenidine and 2-methoxydiphenidine (2-MXP). In the UK, 15 a range of arylcyclohexylamines were placed under control in 2013 following generic 16 legislation [5] but control status varies across the globe. Within one week of 17 introducing generic control, diphenidine was available for purchase in the UK, which 18 For Peer Review 19 added to the existing product catalogues of substances suspected to show [1] 20 dissociative properties in humans. The association of some those newly emerging 21 substances with acute toxicity [6-8] serves as a reminder that the accurate identification 22 of these substances is essential for the monitoring of new psychoactive 23 substances.[9,10] 24 25 26 The major pharmacological mechanism that appears to mediate a significant portion 27 of the therapeutically relevant and psychoactive effects of dissociative substances 28 includes uncompetitive antagonism of the N-methyl-D-aspartate (NMDA) receptor. 29 NMDA receptor antagonists exemplify an important pharmacological class that 30 provides promising pharmacological tools. They are used or are being investigated in 31 a number of therapeutic areas including general anesthetics, neuroprotection, 32 [1,11,12] 33 management of neuropathic pain and depression. Issues linked with clinical 34 tolerability remain challenging for clinical development of this promising 35 pharmacological class.[1,13,14] 36 37 Recently a study of the receptor binding profiles of a series of dissociative legal highs 38 included 3-methoxyeticyclidine (3-MeO-PCE) ( 3b ).[15] Consistent with reports of its 39 [1] 3 40 potent dissociative effects in humans it showed high affinity for (+)-[ H]MK-801 41 labeled NMDA receptors (61 nM). In addition, affinity for the serotonin transporter 42 (115 nM) and lesser affinity at sigma-1 and sigma-2 receptor sites were observed. [15] 43 It is unknown how these additional pharmacological interactions may contribute to 44 the psychoactive properties of 3-MeO-PCE and related arylcyclohexylamines and 45 46 further studies are warranted to explore polypharmacological mechanisms that may 47 be relevant as well. 48 49 N-Alkyl-arylcyclohexylamines including PCE, PCPr and PCiP (Figure 1) were sold on 50 ‘street markets’ during the 1960-1990s in the United States and PCE
Load more

Recommended publications
  • Drug Abuse in Iowa Evolving Issues & Emerging Trends
    1 Drug Abuse in Iowa Evolving Issues & Emerging Trends Iowa Office of Drug Control Policy September 2016 2 Rapid Changes + Mixed Messages = ???s Evolving Risks involving Medicines, Synthetics, Marijuana, etc. • What’s new (what is it, what’s in it, what’s it’s effect)? • Does it heal or hurt (medicine or menace)? • Is it legal or illegal? • What do we tell children (or anyone else) about it? • How is it different now, compared to what I experienced? • What do we know about it & when will we know more? • What’s next? 3 Youth Substance Use 40-Year Trends Current Use (past 30 days) Among U.S. 12th Graders 80% 70% 60% 50% 40% Alcohol 30% Marijuana 20% 10% Cigarettes 0% Monitoring the Future, 1975-2015 4 Drugs of Choice: All Iowans Primary Substance of Choice by Iowans in Treatment 90% 80% 70% 60% Alcohol 50% 50% Marijuana 40% Meth Cocaine 30% 25.6% Heroin Other 20% 14.8% 10% 6.3% 1.7% 0% 1.6% IDPH, 2014 5 Iowa Youth Substance Abuse 6th, 8th and 11th Grade Users, Last 30-Days 25% 23% 20% Alcohol 15% 14% Tobacco 12% Other Drug 9% 10% 10% Rx OTC 6% Meth 5% 4% 4% 3% 3% 1% 0% 1% 2002 2005 2008 2010 2012 2014 Iowa Youth Survey, 2014 6 Iowa Drug-Related Traffic Fatalities Number Killed in 2014 Testing Positive for Illicit Drugs 16 15% of those killed in Iowa traffic fatalities 14 in 2014 tested positive for illicit drugs. 12 10 8 6 4 2 0 Marijuana Meth Rx Synthetic Opium Other Does not include alcohol-related fatalities.
    [Show full text]
  • Moves to Amend HF No. 2711 As Follows
    05/05/20 ​ REVISOR KLL/JK A20-0767​ 1.1 .................... moves to amend H.F. No. 2711 as follows:​ 1.2 Delete everything after the enacting clause and insert:​ 1.3 "ARTICLE 1​ 1.4 APPROPRIATIONS​ 1.5 Section 1. APPROPRIATIONS.​ 1.6 The sums shown in the column under "APPROPRIATIONS" are added to or reduce the​ 1.7 appropriations in Laws 2019, First Special Session chapter 5, to the agencies and for the​ 1.8 purposes specified in this article. The appropriations are from the general fund, or another​ 1.9 named fund, and are available for the fiscal year indicated for each purpose.​ 1.10 APPROPRIATIONS​ 1.11 Available for the Year​ 1.12 Ending June 30​ 1.13 2020​ 2021​ 1.14 Sec. 2. CORRECTIONS​ 1.15 Subdivision 1. Total Appropriation​ $​ 205,000​ $​ 5,545,000​ 1.16 The amounts that may be spent for each​ 1.17 purpose are specified in the following​ 1.18 subdivisions.​ 1.19 Subd. 2. Correctional Institutions​ -0-​ (2,545,000)​ 1.20 To account for overall bed impact savings of​ 1.21 reductions in the penalties for controlled​ 1.22 substances offenses involving the possession​ 1.23 of marijuana, investments in community​ 1.24 supervision, and increased penalties for sex​ 1.25 trafficking offenses, the fiscal year 2021​ Article 1 Sec. 2.​ 1​ 05/05/20 ​ REVISOR KLL/JK A20-0767​ 2.1 appropriation from Laws 2019, First Special​ 2.2 Session chapter 5, article 1, section 15,​ 2.3 subdivision 2, is reduced by $2,545,000.​ 2.4 Subd.
    [Show full text]
  • Sensory and Signaling Mechanisms of Bradykinin, Eicosanoids, Platelet-Activating Factor, and Nitric Oxide in Peripheral Nociceptors
    Physiol Rev 92: 1699–1775, 2012 doi:10.1152/physrev.00048.2010 SENSORY AND SIGNALING MECHANISMS OF BRADYKININ, EICOSANOIDS, PLATELET-ACTIVATING FACTOR, AND NITRIC OXIDE IN PERIPHERAL NOCICEPTORS Gábor Peth˝o and Peter W. Reeh Pharmacodynamics Unit, Department of Pharmacology and Pharmacotherapy, Faculty of Medicine, University of Pécs, Pécs, Hungary; and Institute of Physiology and Pathophysiology, University of Erlangen/Nürnberg, Erlangen, Germany Peth˝o G, Reeh PW. Sensory and Signaling Mechanisms of Bradykinin, Eicosanoids, Platelet-Activating Factor, and Nitric Oxide in Peripheral Nociceptors. Physiol Rev 92: 1699–1775, 2012; doi:10.1152/physrev.00048.2010.—Peripheral mediators can contribute to the development and maintenance of inflammatory and neuropathic pain and its concomitants (hyperalgesia and allodynia) via two mechanisms. Activation Lor excitation by these substances of nociceptive nerve endings or fibers implicates generation of action potentials which then travel to the central nervous system and may induce pain sensation. Sensitization of nociceptors refers to their increased responsiveness to either thermal, mechani- cal, or chemical stimuli that may be translated to corresponding hyperalgesias. This review aims to give an account of the excitatory and sensitizing actions of inflammatory mediators including bradykinin, prostaglandins, thromboxanes, leukotrienes, platelet-activating factor, and nitric oxide on nociceptive primary afferent neurons. Manifestations, receptor molecules, and intracellular signaling mechanisms
    [Show full text]
  • Application of High Resolution Mass Spectrometry for the Screening and Confirmation of Novel Psychoactive Substances Joshua Zolton Seither [email protected]
    Florida International University FIU Digital Commons FIU Electronic Theses and Dissertations University Graduate School 4-25-2018 Application of High Resolution Mass Spectrometry for the Screening and Confirmation of Novel Psychoactive Substances Joshua Zolton Seither [email protected] DOI: 10.25148/etd.FIDC006565 Follow this and additional works at: https://digitalcommons.fiu.edu/etd Part of the Chemistry Commons Recommended Citation Seither, Joshua Zolton, "Application of High Resolution Mass Spectrometry for the Screening and Confirmation of Novel Psychoactive Substances" (2018). FIU Electronic Theses and Dissertations. 3823. https://digitalcommons.fiu.edu/etd/3823 This work is brought to you for free and open access by the University Graduate School at FIU Digital Commons. It has been accepted for inclusion in FIU Electronic Theses and Dissertations by an authorized administrator of FIU Digital Commons. For more information, please contact [email protected]. FLORIDA INTERNATIONAL UNIVERSITY Miami, Florida APPLICATION OF HIGH RESOLUTION MASS SPECTROMETRY FOR THE SCREENING AND CONFIRMATION OF NOVEL PSYCHOACTIVE SUBSTANCES A dissertation submitted in partial fulfillment of the requirements for the degree of DOCTOR OF PHILOSOPHY in CHEMISTRY by Joshua Zolton Seither 2018 To: Dean Michael R. Heithaus College of Arts, Sciences and Education This dissertation, written by Joshua Zolton Seither, and entitled Application of High- Resolution Mass Spectrometry for the Screening and Confirmation of Novel Psychoactive Substances, having been approved in respect to style and intellectual content, is referred to you for judgment. We have read this dissertation and recommend that it be approved. _______________________________________ Piero Gardinali _______________________________________ Bruce McCord _______________________________________ DeEtta Mills _______________________________________ Stanislaw Wnuk _______________________________________ Anthony DeCaprio, Major Professor Date of Defense: April 25, 2018 The dissertation of Joshua Zolton Seither is approved.
    [Show full text]
  • Designer Drugs: a Review
    WORLD JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES Chavan et al. World Journal of Pharmacy and Pharmaceutical Sciences SJIF Impact Factor 5.210 Volume 4, Issue 08, 297-336. Review Article ISSN 2278 – 4357 DESIGNER DRUGS: A REVIEW Dr. Suyash Chavan,MBBS*1 and Dr. Vandana Roy2 1MD, Resident Doctor, Department of Pharmacology, Maulana Azad Medical College, New Delhi. 2MD, PhD Professor, Department of Pharmacology, Maulana Azad Medical College, New Delhi. ABSTRACT Article Received on 25 May 2015, Designer drugs‟ are psychoactive substances that mimic the effects of Revised on 16 June 2015, other banned illicit drugs but evade detection by law enforcing Accepted on 07 July 2015 agencies. This is because of modifications in the structure of the original psychoactive molecule. Originally developed as a way to *Correspondence for evade existing drug laws in the late 1960s, the synthesis and use of Author designer drugs has increased dramatically. They are advertised with Dr. Suyash Chavan innocuous names and are sold mostly over the internet, discreet outlets MD, Resident Doctor, Department of and at entertainment clubs. Victims may exhibit symptoms similar to Pharmacology, Maulana the effects of the illegal drug that these synthetic drugs mimic, Azad Medical College, however, the exact culprit drug is not detected due to structural New Delhi. modifications in the new drug. Overdose of these drugs may lead to serious adverse effects that can be life threatening. Understanding the pharmacology and toxicology of these agents is essential to facilitate their detection and to provide better medical care for patients suffering from adverse effects due to their consumption.
    [Show full text]
  • 16.19.20 Nmac 1 Title 16 Occupational And
    TITLE 16 OCCUPATIONAL AND PROFESSIONAL LICENSING CHAPTER 19 PHARMACISTS PART 20 CONTROLLED SUBSTANCES 16.19.20.1 ISSUING AGENCY: Regulation and Licensing Department - Board of Pharmacy. [16.19.20.1 NMAC - Rp 16.19.20.1 NMAC, 06-26-2018] 16.19.20.2 SCOPE: All persons or entities that manufacture, distribute, dispense, administer, prescribe, deliver, analyze, or conduct research using controlled substances. [16.19.20.2 NMAC - Rp 16.19.20.2 NMAC, 06-26-2018] 16.19.20.3 STATUTORY AUTHORITY: Section 30-31-11 of the Controlled Substances Act, 30-31-1 through 30-31-42 NMSA 1978, authorizes the board of pharmacy to promulgate regulations and charge reasonable fees for the registration and control of the manufacture, distribution and dispensing of controlled substances. [16.19.20.3 NMAC - Rp 16.19.20.3 NMAC, 06-26-2018] 16.19.20.4 DURATION: Permanent. [16.19.20.4 NMAC - Rp 16.19.20.4 NMAC, 06-26-2018] 16.19.20.5 EFFECTIVE DATE: June 26, 2018, unless a different date is cited at the end of a section. [16.19.20.5 NMAC - Rp 16.19.20.5 NMAC, 06-26-2018] 16.19.20.6 OBJECTIVE: The objective of Part 20 of Chapter 19 is to protect the public health and welfare of the citizens of New Mexico by controlling and monitoring access to controlled substances and to give notice of the board’s designation of particular substances as controlled substances. [16.19.20.6 NMAC - Rp 16.19.20.6 NMAC, 06-26-2018] 16.19.20.7 DEFINITIONS: [RESERVED] [16.19.20.7 NMAC - Rp 16.19.20.7 NMAC, 06-26-2018] 16.19.20.8 REGISTRATION REQUIREMENTS: Persons required to register: A.
    [Show full text]
  • Model Scheduling New/Novel Psychoactive Substances Act (Third Edition)
    Model Scheduling New/Novel Psychoactive Substances Act (Third Edition) July 1, 2019. This project was supported by Grant No. G1799ONDCP03A, awarded by the Office of National Drug Control Policy. Points of view or opinions in this document are those of the author and do not necessarily represent the official position or policies of the Office of National Drug Control Policy or the United States Government. © 2019 NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS. This document may be reproduced for non-commercial purposes with full attribution to the National Alliance for Model State Drug Laws. Please contact NAMSDL at [email protected] or (703) 229-4954 with any questions about the Model Language. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: NATIONAL ALLIANCE FOR MODEL STATE DRUG 1 LAWS, 1335 North Front Street, First Floor, Harrisburg, PA, 17102-2629. Model Scheduling New/Novel Psychoactive Substances Act (Third Edition)1 Table of Contents 3 Policy Statement and Background 5 Highlights 6 Section I – Short Title 6 Section II – Purpose 6 Section III – Synthetic Cannabinoids 13 Section IV – Substituted Cathinones 19 Section V – Substituted Phenethylamines 23 Section VI – N-benzyl Phenethylamine Compounds 25 Section VII – Substituted Tryptamines 28 Section VIII – Substituted Phenylcyclohexylamines 30 Section IX – Fentanyl Derivatives 39 Section X – Unclassified NPS 43 Appendix 1 Second edition published in September 2018; first edition published in 2014. Content in red bold first added in third edition. © 2019 NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS. This document may be reproduced for non-commercial purposes with full attribution to the National Alliance for Model State Drug Laws.
    [Show full text]
  • Agenda Florida Hospital Association 307 Park Lake Circle Orlando, FL July 14, 2016 @ 2:00 P.M
    The Florida Board of Nursing Controlled Substances Formulary Committee Agenda Florida Hospital Association 307 Park Lake Circle Orlando, FL July 14, 2016 @ 2:00 p.m. Doreen Cassarino, DNP, ARNP, FNP-BC, BC- ADM, FAANP - Chair Joe Baker, Jr. Executive Director Kathryn L Controlled Substances Formulary Committee Agenda July 14, 2016 @ 2:00 p.m. Committee Members: Doreen Cassarino, DNP, FNP-BC, BC-ADM, FAANP (Chair) Vicky Stone-Gale, DNP, FNP-C, MSN Jim Quinlan, DNP, ARNP Bernardo B. Fernandez, Jr., MD, MBA, FACP Joshua D. Lenchus, DO, RPh, FACP, SFHM Eduardo C. Oliveira, MD, MBA, FCCP Jeffrey Mesaros, PharmD, JD Attorney: Lee Ann Gustafson, Senior Assistant Attorney General Board Staff: Joe Baker, Jr., Executive Director Jessica Hollingsworth, Program Operations Administrator For more information regarding board meetings please visit http://floridasnursing.gov/meeting-information/ Or contact: Florida Board of Nursing 4052 Bald Cypress Way, Bin # C-02 Tallahassee, FL 32399-3252 Direct Line: (850)245-4125/Direct Fax: (850)617-6450 Email: [email protected] Call to Order Roll Call Committee Members: Doreen Cassarino, DNP, FNP-BC, BC-ADM, FAANP (Chair) Vicky Stone-Gale, DNP, FNP-C, MSN Jim Quinlan, DNP, ARNP Bernardo B. Fernandez, Jr., MD, MBA, FACP Joshua D. Lenchus, DO, RPh, FACP, SFHM Eduardo C. Oliveira, MD, MBA, FCCP Jeffrey Mesaros, PharmD, JD Attorney: Lee Ann Gustafson, Senior Assistant Attorney General Board Staff: Joe Baker, Jr., Executive Director Jessica Hollingsworth, Program Operations Administrator I. Review & Approve Minutes from June 29, 2016 Meeting II. Open Discussion A. Recommendations to the Board of Nursing for Rule Promulgation B. Reference Material 1.
    [Show full text]
  • Appendix-2Final.Pdf 663.7 KB
    North West ‘Through the Gate Substance Misuse Services’ Drug Testing Project Appendix 2 – Analytical methodologies Overview Urine samples were analysed using three methodologies. The first methodology (General Screen) was designed to cover a wide range of analytes (drugs) and was used for all analytes other than the synthetic cannabinoid receptor agonists (SCRAs). The analyte coverage included a broad range of commonly prescribed drugs including over the counter medications, commonly misused drugs and metabolites of many of the compounds too. This approach provided a very powerful drug screening tool to investigate drug use/misuse before and whilst in prison. The second methodology (SCRA Screen) was specifically designed for SCRAs and targets only those compounds. This was a very sensitive methodology with a method capability of sub 100pg/ml for over 600 SCRAs and their metabolites. Both methodologies utilised full scan high resolution accurate mass LCMS technologies that allowed a non-targeted approach to data acquisition and the ability to retrospectively review data. The non-targeted approach to data acquisition effectively means that the analyte coverage of the data acquisition was unlimited. The only limiting factors were related to the chemical nature of the analyte being looked for. The analyte must extract in the sample preparation process; it must chromatograph and it must ionise under the conditions used by the mass spectrometer interface. The final limiting factor was presence in the data processing database. The subsequent study of negative MDT samples across the North West and London and the South East used a GCMS methodology for anabolic steroids in addition to the General and SCRA screens.
    [Show full text]
  • Schifano, F., Napoletano, F., Chiappini, S., Orsolini, L., Guirguis, A., Corkery, J
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by University of Hertfordshire Research Archive Citation for the published version: Schifano, F., Napoletano, F., Chiappini, S., Orsolini, L., Guirguis, A., Corkery, J. M., ... vento, A. (2019). New psychoactive substances (NPS), psychedelic experiences, and dissociation: clinical and clinical pharmacological issues. Current Addiction Reports, 6(2), 140-152. https://doi.org/10.1007/s40429-019-00249-z Document Version: Accepted Version The final publication is available at Springer Nature via https://doi.org/10.1007/s40429-019-00249-z © 2019 Springer Nature Publishing AG General rights Copyright© and Moral Rights for the publications made accessible on this site are retained by the individual authors and/or other copyright owners. Please check the manuscript for details of any other licences that may have been applied and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. You may not engage in further distribution of the material for any profitmaking activities or any commercial gain. You may freely distribute both the url (http://uhra.herts.ac.uk/) and the content of this paper for research or private study, educational, or not-for-profit purposes without prior permission or charge. Take down policy If you believe that this document breaches copyright please contact us providing details, any such items will be temporarily removed from the repository pending investigation.
    [Show full text]
  • Alcohol and Drug Abuse Subchapter 9
    Chapter 8 – Alcohol and Drug Abuse Subchapter 9 Regulated Drug Rule 1.0 Authority This rule is established under the authority of 18 V.S.A. §§ 4201 and 4202 which authorizes the Vermont Board of Health to designate regulated drugs for the protection of public health and safety. 2.0 Purpose This rule designates drugs and other chemical substances that are illegal or judged to be potentially fatal or harmful for human consumption unless prescribed and dispensed by a professional licensed to prescribe or dispense them and used in accordance with the prescription. The rule restricts the possession of certain drugs above a specified quantity. The rule also establishes benchmark unlawful dosages for certain drugs to provide a baseline for use by prosecutors to seek enhanced penalties for possession of higher quantities of the drug in accordance with multipliers found at 18 V.S.A. § 4234. 3.0 Definitions 3.1 “Analog” means one of a group of chemical components similar in structure but different with respect to elemental composition. It can differ in one or more atoms, functional groups or substructures, which are replaced with other atoms, groups or substructures. 3.2 “Benchmark Unlawful Dosage” means the quantity of a drug commonly consumed over a twenty-four-hour period for any therapeutic purpose, as established by the manufacturer of the drug. Benchmark Unlawful dosage is not a medical or pharmacologic concept with any implication for medical practice. Instead, it is a legal concept established only for the purpose of calculating penalties for improper sale, possession, or dispensing of drugs pursuant to 18 V.S.A.
    [Show full text]
  • G.S. 90-89 Page 1 § 90-89. Schedule I Controlled Substances. This
    § 90-89. Schedule I controlled substances. This schedule includes the controlled substances listed or to be listed by whatever official name, common or usual name, chemical name, or trade name designated. In determining that a substance comes within this schedule, the Commission shall find: a high potential for abuse, no currently accepted medical use in the United States, or a lack of accepted safety for use in treatment under medical supervision. The following controlled substances are included in this schedule: (1) Opiates. – Any of the following opiates or opioids, including the isomers, esters, ethers, salts and salts of isomers, esters, and ethers, unless specifically excepted, or listed in another schedule, whenever the existence of such isomers, esters, ethers, and salts is possible within the specific chemical designation: a. Acetyl-alpha-methylfentanyl (N[1-(1-methyl-2-phenethyl)-4-piperidinyl]-N-phenylacet amide). b. Acetylmethadol. c. Repealed by Session Laws 1987, c. 412, s. 2. d. Alpha-methylthiofentanyl (N-[1-methyl-2-(2-thienyl)ethyl/-4-piperidinyl]-N-phenylpro panamide). e. Allylprodine. f. Alphacetylmethadol (except levo-alphacetylmethadol, also known as levomethadyl acetate and LAAM). g. Alphameprodine. h. Alphamethadol. i. Alpha-methylfentanyl (N-(1-(alpha-methyl-beta-phenyl) ethyl-4-piperidyl) propionalilide; 1(1-methyl-2-phenyl-ethyl)-4-(N-propanilido) piperidine). j. Benzethidine. k. Betacetylmethadol. l. Beta-hydroxfentanyl (N-[1-(2-hydroxy-2-phenethyl)-4-piperidinyl]-N-phenylpropanamide ). m. Beta-hydroxy-3-methylfentanyl (N-[1-(2-hydroxy-2-phenethyl)-3-methyl-4-piperidinyl]-N-phenylpro panamide). n. Betameprodine. o. Betamethadol. p. Betaprodine. q. Clonitazene. r. Dextromoramide. s. Diampromide. t. Diethylthiambutene. u.
    [Show full text]